| Literature DB >> 31557843 |
Ann M Kemper1, Jenny Drnevich2, Molly E McCue3, Annette M McCoy4.
Abstract
Skeletogenesis is complex and incompletely understood. Derangement of this process likely underlies developmental skeletal pathologies. Examination of tissue-specific gene expression may help elucidate novel skeletal developmental pathways that could contribute to disease risk. Our aim was to identify and functionally annotate differentially expressed genes in equine neonatal and adult articular cartilage (AC) and subchondral bone (SCB). RNA was sequenced from healthy AC and SCB from the fetlock, hock, and stifle joints of 6 foals (≤4 weeks of age) and six adults (8-12 years of age). There was distinct clustering by age and tissue type. After differential expression analysis, functional annotation and pathway analysis were performed using PANTHER and Reactome. Approximately 1115 and 3574 genes were differentially expressed between age groups in AC and SCB, respectively, falling within dozens of overrepresented gene ontology terms and enriched pathways reflecting a state of growth, high metabolic activity, and tissue turnover in the foals. Enriched pathways were dominated by those related to extracellular matrix organization and turnover, and cell cycle and signal transduction. Additionally, we identified enriched pathways related to neural development and neurotransmission in AC and innate immunity in SCB. These represent novel potential mechanisms for disease that can be explored in future work.Entities:
Keywords: developmental orthopedic disease; equine; joints; skeletal development; transcriptome
Mesh:
Year: 2019 PMID: 31557843 PMCID: PMC6826356 DOI: 10.3390/genes10100745
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Multidimensional scaling (MDS) was run on normalized gene expression values (logCPM) after removing the effects of the surrogate variables to cluster the (A) articular cartilage samples; and (B) subchondral bone samples to get an overview of similarities and differences between samples. Each samples’ age and location are indicated by point shape and color, respectively. Locations are F = fetlock (metatarsophalangeal joint), H = hock (tarsocrural joint), and S = stifle (femoropatellar joint).
Number of DE genes with FC > |1.5| and global FDR p < 0.05 in articular cartilage and subchondral bone. DE is calculated by joint location. F = fetlock (metatarsophalangeal joint); H = hock (tarsocrural joint); S = stifle (femoropatellar joint).
| Foal.F vs. Adult.F | Foal.H vs. Adult.H | Foal.S vs. Adult.S | ||
|---|---|---|---|---|
| Articular Cartilage | Down | 212 | 288 | 260 |
| Not Significant | 15,832 | 15,785 | 15,831 | |
| Up | 396 | 367 | 349 | |
| Subchondral Bone | Down | 1343 | 1360 | 1250 |
| Not Significant | 15,461 | 15,296 | 15,606 | |
| Up | 1205 | 1353 | 1153 |
Figure 2Venn diagrams showing overlap between differentially expressed (DE) genes in the three joint locations in (A) articular cartilage (AC) and (B) subchondral bone (SCB). Percentages are in reference to the total number of unique DE genes in each tissue (1115 genes in AC, 3574 in SCB).
Overrepresented GO-Slim terms among differentially expressed genes in AC. The reference list is Homo sapiens UniProt IDs and includes 20996 genes; the analyzed list is comprised of the UniProt IDs for 965 DE genes identified from AC samples. FDR = false discovery rate (significance set at 0.05). A complete hierarchical list of overrepresented terms can be found in Table S4.
| Genes in Reference List | Genes in Analyzed List | Fold Enrichment | Raw | FDR | |
|---|---|---|---|---|---|
| GO-Slim Biological Process | |||||
| extracellular matrix organization (GO:0030198) | 69 | 16 | 5.05 | 7.76 × 10−7 | 0.0002 |
| microtubule-based movement (GO:0007018) | 87 | 15 | 3.75 | 3.85 × 10−5 | 0.0041 |
| regulation of axonogenesis (GO:0050770) | 27 | 8 | 6.45 | 1.10 × 10−4 | 0.007 |
| chemical synaptic transmission (GO:0007268) | 330 | 33 | 2.18 | 8.10 × 10−5 | 0.0073 |
| postitive regulation of synaptic transmission (GO:0050806) | 24 | 7 | 6.35 | 3.22 × 10−4 | 0.017 |
| cell adhesion (GO:0007155) | 373 | 34 | 1.98 | 3.39 × 10−4 | 0.017 |
| Wnt signaling pathway (GO:0016055) | 98 | 14 | 3.11 | 3.98 × 10−4 | 0.018 |
| positive regulation of signal transduction (GO:0009967) | 112 | 15 | 2.91 | 4.65 × 10−4 | 0.018 |
| tissue development (GO:0009888) | 117 | 15 | 2.79 | 7.01 × 10−4 | 0.026 |
| angiogenesis (GO:0001525) | 30 | 7 | 5.08 | 1.00 × 10−3 | 0.035 |
| regulation of chemotaxis (GO:0050920) | 22 | 6 | 5.93 | 1.16 × 10−3 | 0.039 |
| axonogenesis (GO:0007409) | 98 | 13 | 2.89 | 1.18 × 10−3 | 0.039 |
| amino acid transport (GO:0007416) | 15 | 5 | 7.25 | 1.45 × 10−3 | 0.044 |
| Notch signaling pathway (GO:0007219) | 32 | 7 | 4.76 | 1.39 × 10−3 | 0.044 |
| dendritic spine organization (GO:0097061) | 3 | 3 | 21.76 | 1.53 × 10−3 | 0.045 |
| synapse assembly (GO:0007416) | 15 | 5 | 7.25 | 1.45 × 10−3 | 0.045 |
| negative regulation of neurogenesis (GO:0050768) | 24 | 6 | 5.44 | 1.70 × 10−3 | 0.048 |
| GO-Slim Molecular Function | |||||
| extracellular matrix structural component (GO:0005201) | 53 | 17 | 6.98 | 6.46 × 10−9 | 3.26 × 10−6 |
| microtubule binding (GO:0008017) | 123 | 17 | 3.01 | 1.43 × 10−4 | 0.01 |
| transmembrane receptor protein kinase activity (GO:0019199) | 62 | 10 | 3.51 | 1.16 × 10−3 | 0.031 |
| cation transmembrane transporter activity (GO:0008324) | 449 | 37 | 1.79 | 1.10 × 10−3 | 0.031 |
| metallopeptidase activity (GO:0008237) | 103 | 14 | 2.96 | 6.23 × 10−4 | 0.035 |
| calcium ion binding (GO:0005509) | 205 | 21 | 2.23 | 1.46 × 10−3 | 0.037 |
| cadherin binding (GO:0045296) | 43 | 8 | 4.05 | 1.60 × 10−3 | 0.039 |
| peptidase inhibitor activity (GO:0030414) | 117 | 14 | 2.6 | 1.88 × 10−3 | 0.043 |
| ATP-dependent microtubule motor activity, plus-end-directed (GO:0008574) | 25 | 6 | 5.22 | 2.03 × 10−3 | 0.045 |
| gated channel activity (GO:0022836) | 160 | 17 | 2.31 | 2.45 × 10−3 | 0.046 |
| GO-Slim Cellular Component | |||||
| collagen trimer (GO:0005581) | 10 | 6 | 13.05 | 3.88 × 10−5 | 0.0022 |
| microtubule associated complex (GO:0005875) | 58 | 12 | 4.5 | 4.89 × 10−5 | 0.0022 |
| extrinsic component of plasma membrane (GO:0019897) | 28 | 8 | 6.22 | 1.36 × 10−4 | 0.0041 |
| cell-cell junction (GO: 0005911) | 70 | 12 | 3.73 | 2.35 × 10−4 | 0.0066 |
| cation channel complex (GO:0034703) | 94 | 14 | 3.24 | 2.72 × 10−4 | 0.0072 |
| microtubule (GO:0005874) | 162 | 19 | 2.55 | 4.04 × 10−4 | 0.0095 |
| postsynaptic density (GO:0014069) | 46 | 9 | 4.26 | 6.06 × 10−4 | 0.013 |
| postsynaptic membrane (GO:0045211) | 58 | 10 | 3.75 | 7.35 × 10−4 | 0.015 |
| ionotropic glutamate receptor complex (GO:0008328) | 33 | 7 | 4.62 | 1.62 × 10−3 | 0.029 |
| extracellular space (GO:0005615) | 863 | 61 | 1.54 | 1.73 × 10−3 | 0.029 |
| basement membrane (GO:0005604) | 4 | 3 | 16.32 | 2.59 × 10−3 | 0.036 |
Results from pathway analysis in PANTHER and Reactome. Adjacent pathways sharing the same background color are hierarchically related to each other in the PANTHER analysis. Fold-enrichment is not reported by Reactome (NA = not applicable). FDR = false discovery rate; ECM = extracellular matrix; R-HSA-XXX = Reactome pathway identifiers.
| Pathway | Genes in Reference List | Genes in Analyzed List | Fold Enrichment | Raw | FDR |
|---|---|---|---|---|---|
| PANTHER | |||||
| Collagen chain trimerization (R-HSA-8948216) | 44 | 14 | 6.92 | 1.52 × 10−7 | 4.15 × 10−5 |
| Collagen biosynthesis and modifying enzymes (R-HSA-1650814) | 67 | 18 | 5.85 | 2.38 × 10−8 | 8.68 × 10−6 |
| Collagen formation (R-HSA-1474290) | 89 | 21 | 5.13 | 1.17 × 10−8 | 8.53 × 10−6 |
| ECM organization (R-HSA-1474244) | 299 | 54 | 3.93 | 1.02 × 10−15 | 2.25 × 10−12 |
| NCAM1 interactions (R-HSA-8948216) | 42 | 13 | 6.73 | 5.48 × 10−7 | 0.0001 |
| NCAM signaling for neurite outgrowth (R-HSA-375165) | 60 | 14 | 5.08 | 3.54 × 10−6 | 0.00055 |
| Axon guidance (R-HSA-422475) | 550 | 52 | 2.06 | 3.97 × 10−6 | 0.00058 |
| Collagen degradation (R-HSA-1442490) | 64 | 16 | 5.44 | 3.27 × 10−7 | 7.16 × 10−5 |
| Degradation of the ECM (R-HSA-1474228) | 140 | 26 | 4.04 | 1.73 × 10−8 | 9.48 × 10−6 |
| Assembly of collagen fibrils and other multimeric structures (R-HSA-2022090) | 60 | 15 | 5.44 | 7.60 × 10−7 | 0.00013 |
| Integrin cell surface interactions (R-HSA-216083) | 84 | 20 | 5.18 | 2.28 × 10−8 | 9.99 × 10−6 |
| ECM proteoglycans (R-HSA-3000178) | 76 | 17 | 4.87 | 5.46 × 10−7 | 0.00011 |
| Kinesins (R-HSA-983189) | 61 | 13 | 4.64 | 1.82 × 10−5 | 0.0025 |
| Hemostasis (R-HSA-109582) | 671 | 54 | 1.75 | 1.99 × 10−4 | 0.021 |
| Elastic fibril formation (R-HSA-1566948) | 45 | 9 | 4.35 | 5.27 × 10−4 | 0.046 |
| Neurotransmitter receptors and postsynaptic signal transmission (R-HSA-112314) | 148 | 19 | 2.79 | 1.43 × 10−4 | 0.017 |
| Transmission across chemical synapses (R-HSA-112315) | 218 | 26 | 2.59 | 4.57 × 10−5 | 0.0056 |
| Neuronal system (R-HSA-112316) | 361 | 42 | 2.53 | 2.29 × 10−7 | 5.57 × 10−5 |
| Reactome | |||||
| ECM organization (R-HSA-1474244) | 329 | 54 | NA | 1.26 × 10−8 | 1.49 × 10−5 |
| Collagen chain trimerization (R-HSA-8948216) | 44 | 14 | 3.95 × 10−6 | 0.0017 | |
| Integrin cell surface interactions (R-HSA-216083) | 86 | 20 | 4.40 × 10−6 | 0.0017 | |
| Collagen biosynthesis and modifying enzymes (R-HSA-1650814) | 76 | 18 | 1.02 × 10−5 | 0.003 | |
| NCAM1 interactions (R-HSA-419037) | 44 | 13 | 1.86 × 10−5 | 0.0041 | |
| Collagen formation (R-HSA-1474290) | 104 | 21 | 2.07 × 10−5 | 0.0041 | |
| Degradation of the ECM (R-HSA-1474228) | 148 | 26 | 2.45 × 10−5 | 0.0041 | |
| Collagen degradation (R-HSA-1442490) | 69 | 16 | 4.00 × 10−5 | 0.0059 | |
| ECM proteoglycans (R-HSA-3000178) | 79 | 17 | 5.75 × 10−5 | 0.0075 | |
| Assembly of collagen fibrils and other multimeric structures (R-HSA-2022090) | 67 | 15 | 1.00 × 10−4 | 0.012 | |
| NCAM signaling for neurite out-growth (R-HSA-375165) | 69 | 14 | 4.46 × 10−4 | 0.048 | |
Genes found within enriched pathways identified by both PANTHER and Reactome based on DE in articular cartilage. Only 3 out of 60 genes were found in a single pathway, while 8 genes (all collagen subtypes) were found in all enriched pathways. For each gene “x” designates the pathway(s) in which it was found.
| Gene Family | Gene Symbol(s) | ECM Organization | Collagen Chain Trimerization | Collagen Biosynthesis and Modifying Enzymes | Collagen Formation | Degradation of the ECM | Collagen Degradation | ECM Proteoglycans | Assembly of Collagen Fibrils and Other Multimeric Structures | Integrin Cell Surface Interactions | NCAM1 Interactions | NCAM Signaling for Neurite Outgrowth |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upregulated in foals | ||||||||||||
| ADAM metallopeptidase domain | ADAM12 | x | ||||||||||
| ADAM metallopeptidase with thrombospondin | ADAMTS2 | x | x | x | ||||||||
| ADAMTS8 | x | x | ||||||||||
| Calcium voltage-gated channel subunit | CACNA1G | x | x | |||||||||
| Calpain | CAPN6 | x | x | |||||||||
| Collagen | COL2A1 | x | x | x | x | x | x | x | x | x | x | x |
| COL8A1 | x | x | x | x | x | x | x | x | ||||
| COL11A1 | x | x | x | x | x | x | ||||||
| COL16A1 | x | x | x | x | x | x | x | |||||
| COL18A1 | x | x | x | x | x | x | x | x | ||||
| COL21A1 | x | x | x | x | ||||||||
| Elastin | ELN | x | x | |||||||||
| Immunoglobulin superfamily | F11R | x | x | |||||||||
| NCAM1 | x | x | x | x | ||||||||
| Fibulin | FBLN2 | x | ||||||||||
| Fibrillin | FBN2 | x | x | |||||||||
| Hyaluronan and proteoglycan link protein | HAPLN1 | x | x | |||||||||
| Heparain sulfate proteoglycan | HSPG2 | x | x | x | x | |||||||
| Integrin subunit | ITGA10 | x | x | |||||||||
| VEGF receptor | KDR | x | x | |||||||||
| Lysyl oxidase | LOXL2 | x | x | |||||||||
| Matrilin | MATN1 | x | x | |||||||||
| Microfibrillar associated protein | MFAP2 | x | ||||||||||
| Matrix metalloproteinase | MMP2 | x | x | x | ||||||||
| MMP9 | x | x | x | x | x | |||||||
| Nidogen | NID2 | x | ||||||||||
| Platelet and endothelial cell adhesion molecule | PECAM1 | x | x | |||||||||
| Serpin | SERPINH1 | x | x | x | ||||||||
| Secreted protein acidic and cysteine rich | SPARC | x | x | |||||||||
| Spectrin | SPTBN2 | x | ||||||||||
| Downregulated in foals | ||||||||||||
| Calpain | CAPN2 | x | x | |||||||||
| Transmembrane 4 superfamily | CD151 | x | x | x | ||||||||
| Collagen | COL4A3 | x | x | x | x | x | x | x | x | x | x | x |
| COL6A5 | x | x | x | x | x | x | x | x | x | x | x | |
| Small leucine-rich proteoglycan | DCN | x | x | x | ||||||||
| Integrin subunit | ITGA3 | x | x | |||||||||
| ITGB5 | x | x | x | |||||||||
| latent TGFb binding protein | LTB2 | x | ||||||||||
| Procollagen C-endopeptidase enhancer | PCOLCE2 | x | x | x | ||||||||
| Prion protein | PRNP | x | x | |||||||||
| Signal peptide, CUB domain and EGF-like domain | SCUBE1 | x | x | |||||||||
| Secreted phosphoprotein | SPP1 | x | x | x | ||||||||
| Sialyltransferase | ST8SIA4 | x | x | |||||||||
| Tissue inhibitor of metalloproteinase | TIMP2 | x | x | |||||||||
| Tenascin | TNXB | x | x | |||||||||
Overrepresented GO-Slim terms among DE genes in SCB. The reference list is Homo sapiens UniProt IDs and includes 20996 genes; the analyzed list is comprised of the UniProt IDs for 2923 DE genes identified from SCB samples. FDR = false discovery rate (significance set at 0.05). A complete hierarchical list of overrepresented terms can be found in Table S6.
| Genes in Reference List | Genes in Analyzed List | Fold Enrichment | Raw | FDR | |
|---|---|---|---|---|---|
| GO-Slim Biological Process | |||||
| mitotic nuclear division (GO:0140014) | 209 | 63 | 2.17 | 5.19 × 10−7 | 8.47 × 10−5 |
| positive regulation of cytosolic calcium ion concentration (GO:0007204) | 65 | 24 | 2.65 | 1.33 × 10−4 | 0.0096 |
| inflammatory response (GO:0006954) | 101 | 32 | 2.28 | 1.50 × 10−4 | 0.01 |
| intracellular signal transduction (GO:0035556) | 777 | 151 | 1.4 | 2.24 × 10−4 | 0.013 |
| extracellular matrix organization (GO:0030198) | 69 | 24 | 2.5 | 3.32 × 10−4 | 0.018 |
| tissue development (GO:0009888) | 117 | 34 | 2.09 | 3.93 × 10−4 | 0.02 |
| cytoskeleton organization (GO:0007010) | 226 | 55 | 1.75 | 4.47 × 10−4 | 0.021 |
| regulation of cell proliferation (GO:0042127) | 96 | 29 | 2.17 | 5.34 × 10−4 | 0.022 |
| transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169) | 197 | 49 | 1.79 | 5.51 × 10−4 | 0.022 |
| cell migration (GO:0016477) | 177 | 45 | 1.83 | 6.07 × 10−4 | 0.024 |
| neuron development (GO:0048666) | 172 | 44 | 1.84 | 7.42 × 10−4 | 0.028 |
| cell-cell adhesion (GO:0098609) | 104 | 30 | 2.07 | 8.37 × 10−4 | 0.03 |
| regulation of mitotic nuclear division (GO:0007088) | 26 | 12 | 3.32 | 1.37 × 10−3 | 0.044 |
| GO-Slim Molecular Function | |||||
| extracellular matrix structural component (GO:0005201) | 53 | 22 | 2.98 | 3.00 × 10−5 | 0.0034 |
| oxidoreductase activity (GO:0016491) | 527 | 111 | 1.51 | 1.08 × 10−4 | 0.0055 |
| cytokine receptor activity (GO:0004896) | 69 | 25 | 2.6 | 1.81 × 10−4 | 0.0076 |
| G-protein coupled peptide receptor activity (GO:0008528) | 76 | 25 | 2.36 | 5.99 × 10−4 | 0.014 |
| calcium ion binding (GO:0005509) | 205 | 51 | 1.79 | 4.92 × 10−4 | 0.014 |
| growth factor binding (GO:0019838) | 46 | 18 | 2.81 | 7.18 × 10−4 | 0.017 |
| actin filament binding (GO:0051015) | 65 | 21 | 2.32 | 1.49 × 10−3 | 0.029 |
| transmembrane receptor protein kinase activity (GO:0004714) | 60 | 20 | 2.39 | 1.60 × 10−3 | 0.03 |
| peptidase inhibitor activity (GO:0030414) | 117 | 32 | 1.96 | 1.48 × 10−3 | 0.03 |
| C-C chemokine binding (GO:0019957) | 24 | 11 | 3.29 | 2.25 × 10−3 | 0.038 |
| metallopeptidase activity (GO:0008237) | 103 | 28 | 1.95 | 2.91 × 10−3 | 0.043 |
| GO-Slim Cellular Component | |||||
| integral component of plasma membrane (GO:0005887) | 733 | 165 | 1.62 | 5.71 × 10−8 | 1.28 × 10−5 |
| collagen-containing ECM (GO:0062023) | 33 | 15 | 3.27 | 4.09 × 10−4 | 0.0087 |
| receptor complex (GO:0043235) | 177 | 45 | 1.83 | 6.07 × 10−4 | 0.011 |
| focal adhesion (GO:0005925) | 25 | 12 | 3.45 | 1.05 × 10−3 | 0.016 |
| condensed nuclear chromosome kinetochore (GO:0000778) | 9 | 7 | 5.59 | 1.69 × 10−3 | 0.022 |
| microtubule (GO:0005874) | 162 | 40 | 1.77 | 2.30 × 10−3 | 0.025 |
| extracellular space (GO:0005615) | 863 | 157 | 1.31 | 2.06 × 10−3 | 0.025 |
| cyclin-dependent protein kinase holoenzyme complex (GO:0000307) | 28 | 12 | 3.08 | 2.24 × 10−3 | 0.026 |
| spindle (GO:0005819) | 46 | 16 | 2.5 | 2.91 × 10−3 | 0.03 |
| cell surface (GO:0009986) | 322 | 67 | 1.49 | 3.75 × 10−3 | 0.038 |
Results from pathway analysis in PANTHER and Reactome. Only the top 25 (by FDR) terminal hierarchical pathways from the PANTHER analysis are listed here; the complete hierarchical list of enriched pathways can be found in Table S7. Fold-enrichment is not reported by Reactome (NA = not applicable). FDR = false discovery rate; ECM = extracellular matrix; R-HSA-XXX = Reactome pathway identifiers.
| Pathway | Genes in Reference List | Genes in Analyzed List | Fold Enrichment | Raw | FDR |
|---|---|---|---|---|---|
| PANTHER | |||||
| Neutrophil degranulation (R-HSA-6798695) | 479 | 167 | 2.5 | 1.2 × 10−21 | 1.31 × 10−18 |
| Resolution of sister chromatid cohesion (R-HSA-2500257) | 122 | 50 | 2.94 | 2.69 × 10−9 | 4.54 × 10−7 |
| RHO GTPases activate formins (R-HSA-5663220) | 135 | 51 | 2.71 | 2.52 × 10−8 | 3.25 × 10−6 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal (R-HSA-141444) | 92 | 39 | 3.04 | 1.05 × 10−7 | 1.15 × 10−5 |
| Integrin cell surface interactions (R-HSA-216083) | 84 | 36 | 3.08 | 1.73 × 10−7 | 1.65 × 10−5 |
| ECM proteoglycans (R-HSA-3000178) | 76 | 31 | 2.93 | 3.60 × 10−6 | 2.46 × 10−4 |
| Deposition of new CENPA-containing nucleosomes at the centromere (R-HSA-606279) | 54 | 25 | 3.33 | 4.40 × 10−6 | 3.60 × 10−4 |
| Non-integrin membrane-ECM interactions (R-HSA-3000171) | 59 | 26 | 3.17 | 5.76 × 10−6 | 3.60 × 10−4 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) (R-HSA-5083635) | 38 | 20 | 3.78 | 9.26 × 10−6 | 5.63 × 10−4 |
| O-glycosylation of TSR domain-containing proteins (R-HSA-5173214) | 39 | 20 | 3.68 | 1.24 × 10−5 | 7.35 × 10−4 |
| Collagen degradation (R-HSA-1442490) | 64 | 25 | 2.81 | 5.24 × 10−5 | 0.0026 |
| Assembly of collagen fibrils and other multimeric structures (R-HSA-2022090) | 60 | 24 | 2.87 | 6.26 × 10−5 | 0.0029 |
| Kinesins (R-HSA-983189) | 61 | 24 | 2.83 | 7.11 × 10−5 | 0.0033 |
| NCAM1 interactions (R-HSA-419037) | 42 | 19 | 3.25 | 7.67 × 10−5 | 0.033 |
| Molecules associated with elastic fibres (R-HSA-2129379) | 38 | 18 | 3.4 | 7.43 × 10−5 | 0.0033 |
| Separation of sister chromatids (R-HSA-2467813) | 186 | 50 | 1.93 | 8.50 × 10−5 | 0.0035 |
| GPVI-mediated activation cascade (R-HSA-114604) | 35 | 17 | 3.49 | 9.21 × 10−5 | 0.0037 |
| Platelet degranuation (R-HSA-114608) | 127 | 38 | 2.15 | 1.04 × 10−4 | 0.0039 |
| Cell surface interactions at the vascular wall (R-HSA-202733) | 198 | 50 | 1.81 | 3.96 × 10−4 | 0.012 |
| Laminin interactions (R-HSA-3000157) | 30 | 14 | 3.35 | 5.15 × 10−4 | 0.015 |
| Constituative signaling by aberrant PI3K in cancer (R-HSA-2219530) | 55 | 20 | 2.61 | 5.72 × 10−4 | 0.016 |
| Metabolism of folate and pterines (R-HSA-196757) | 16 | 10 | 4.49 | 6.05 × 10−4 | 0.016 |
| MyD88 deficiency (TLR2/4) (R-HSA-5602498) | 10 | 8 | 5.75 | 6.91 × 10−4 | 0.018 |
| Neuronal system (R-HSA-112316) | 361 | 78 | 1.55 | 6.78 × 10−4 | 0.018 |
| Signaling by interleukins (R-HSA-449147) | 449 | 93 | 1.49 | 6.88 × 10−4 | 0.018 |
| Reactome | |||||
| Neutrophil degranulation (R-HSA-6798695) | 480 | 164 | NA | 1.47 × 10−9 | 2.79 × 10−6 |
| RHO GTPase effectors (R-HSA-195258) | 326 | 105 | 1.49 × 10−5 | 0.014 | |
| ECM organization (R-HSA-1474244) | 329 | 105 | 2.13 × 10−5 | 0.014 | |
| Signaling by RHO GTPases (R-HSA-194315) | 457 | 136 | 3.79 × 10−5 | 0.018 | |
| Aplification of signal from the kinetochores (R-HSA-141424) | 94 | 39 | 6.82 × 10−5 | 0.022 | |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal (R-HSA-141444) | 94 | 39 | 6.82 × 10−5 | 0.022 | |
| Resolution of sister chromatid cohesion (R-HSA-2500257) | 134 | 50 | 9.86 × 10−5 | 0.025 | |
| Integrin cell surface interactions (R-HSA-216083) | 86 | 36 | 1.07 × 10−4 | 0.025 | |
| Deposition of new CENPA-containing nucleosomes at the centromere (R-HSA-606279) | 54 | 25 | 2.71 × 10−4 | 0.052 | |
| Nucleosome assembly (R-HSA-774815) | 54 | 25 | 2.71 × 10−4 | 0.052 | |
| Defective B3GALTL causes Peters-plus syndrome (PpS) (R-HSA-5083635) | 39 | 20 | 3.04 × 10−4 | 0.052 | |